PRAF2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma
PRAF2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma
复制标题
PRAF2过表达预示食管鳞状细胞癌预后不良并促进肿瘤发生
DOI：
10.1186/s12885-019-5818-7
复制
发表时间：
2019-06-14
期刊：
影响因子：
3.8
通讯作者：
Chen, Xiaofei
中科院分区：
文献类型：
--
作者：
Qian, Zhaoye;Wei, Bin;Chen, Xiaofei
研究背景异戊烯化Rab受体1域家族成员2（Prenylated Rab receptor 1 domain family，member 2，PRAF 2）参与多种恶性肿瘤的发生和发展。方法采用定量逆转录-聚合酶链反应（qPCR）技术检测77例食管鳞癌组织中PRAF 2 mRNA的表达，并分析其与食管鳞癌临床特征及总生存期的关系。结果PRAF 2 mRNA在食管鳞癌组织中的表达明显高于癌旁正常组织。生存分析显示PRAF 2 mRNA高表达与ESCC患者的总体生存率相关。多因素分析显示，PRAF 2（hazardratio 2.05，95%CI 1.10- 3.85，P = 0.025）是食管鳞癌患者总生存率低的独立预测因子。体外实验表明，敲低PRAF 2表达阻断细胞增殖，细胞周期进程和细胞侵袭，并诱导细胞凋亡在ESCC cells. ConclusionTogether，我们的数据表明，PRAF 2可以被用作一个潜在的预后生物标志物，并代表一个潜在的治疗ESCC的目标。
BackgroundPrenylated Rab acceptor 1 domain family, member 2 (PRAF2) is involved in the occurrence and progression of several malignant tumors. However, its potential role in esophageal squamous cell carcinoma (ESCC) is still unknown.MethodsPRAF2 mRNA expression was determined in 77 frozen ESCC samples by quantitative reverse transcription-polymerase chain reaction (qPCR) and its association with clinical features and overall survival were evaluated. The roles of PRAF2 in ESCC cells were investigated by proliferation, cell cycle, invasion and apoptosis assays in vitro.ResultsThe PRAF2 mRNA expression was significantly increased in ESCC tissues compared with matched surrounding non-tumor tissues. Survival analysis showed that high PRAF2 mRNA expression was associated with worse overall survival in ESCC patients. Multivariate analysis revealed that PRAF2 (hazard ratio 2.05, 95% CI 1.10–3.85,P= 0.025) emerged as the independent predictor for poor overall survival in ESCC. The in vitro experiments revealed that knockdown of PRAF2 expression blocked cell proliferation, cell cycle progression and cell invasion and induced cell apoptosis in ESCC cells.ConclusionTaken together, our data demonstrate that PRAF2 could be used as a potential prognostic biomarker and represent a potential therapeutic target for ESCC.